mRNA Vaccines and RNAi Therapeutics Market Expected to Reach $12.31 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “mRNA Vaccines and RNAi Therapeutics Market," The mRNA vaccines and RNAi therapeutics market was valued at $707.97 million in 2021, and is estimated to reach $12.31 billion by 2031, growing at a CAGR of 31.3% from 2022 to 2031.

mRNA vaccines and RNAi therapeutics have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, there has been development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines and RNAi therapeutics are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Thus, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nano emulsion), naked mRNA vaccines and dendritic cell-based mRNA vaccines.
 
The key factors that drive the mRNA vaccines and RNAi therapeutics market growth is increase in prevalence of chronic disease and infectious disease, initiatives taken by government for large scale sequencing projects.
In addition, target specialty and selectivity of treatment and increasing awareness about vaccination are some mRNA vaccines and RNAi therapeutics market trends  which further expected to boost the mRNA vaccines and RNAi therapeutics market size growth during forecast period. However, high cost of research, threat of failure and challenges in quantification of mRNA is expected to hamper the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, applications of mRNA technology and development of mRNA biomarker are expected to provide numerous opportunities for market growth during the forecast period.

By disease type, the hereditary transthyretin-mediated amyloidosis genetic segment dominated the mRNA vaccines and RNAi therapeutics market share in 2021 and is expected to remain dominant during the forecast period. This is attributed to the rise in demand for the treatment of ATTR amyloidosis owing to, increase in prevalence and increasing need for the treatment of fatal disease. In addition, increase in awareness, improvement in diagnostic procedures, improvement in health care services, rapid economic growth in developing countries, and rise in R&D activities further boost the market growth. On the other side, Atherosclerotic cardiovascular disease is projected to exhibit the fastest market growth during the forecast period, owing to high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries. 

Depending on route of administration, the IV infusion segment was the major revenue contributor in mRNA vaccines industry and RNAi therapeutics industry, and is anticipated to continue this trend during the forecast period, owing to increase in adoption of IV infusion for administration of vaccines and therapeutics. On the other side, subcutaneous segment is projected to exhibit the fastest market growth during the forecast period owing to cost effectiveness of subcutaneous route of administration as compare to IV infusion.

By end user, the hospitals & clinics segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to increase in number of patients with respiratory disease, cancer and infectious disease. Furthermore, the research institutes segment is projected to show fastest growth during the forecast period, due to collaboration of research organizations and research institutes or collaborating with government bodies to bear the high cost of research.

Region wise, North America has the highest market share in 2021 registering a CAGR of 31.1% during the forecast period. This is attributed to the well-established healthcare system, increase in number of geriatric patients, and supportive reimbursement policies in healthcare system and increasing number of healthcare facilities offering mRNA vaccines and RNAi therapeutics. Asia-Pacific is projected to register the highest CAGR of 33.9% during the forecast period. The presence of a large population base, increasing per capita income, growing medical tourism industry, and rising public awareness regarding benefits of mRNA vaccine and RNAi therapeutics are the key driving factors that boost the growth of the market in the region.

KEY FINDINGS OF STUDY
• On the basis of disease type, the hereditary transthyretin-mediated amyloidosis genetic segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
• On the basis of route of administration, the IV infusion segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
• Depending on end user, hospitals and clinics segment is projected to grow at a CAGR of 31.6% during the forecast period.
• Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 33.9% during the forecast period.